Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug 14;71(4):1099-1101.
doi: 10.1093/cid/ciz1159.

Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Ryan K Shields  1   2 , Yohei Doi  1   2   3
Affiliations
Comment

Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Ryan K Shields et al. Clin Infect Dis. .
No abstract available

Keywords: beta-lactamase inhibitor; carbapenemase; monobactam; pharmacokinetics.

PubMed Disclaimer

Comment on

References

    1. Bonomo RA, Burd EM, Conly J, et al. . Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 2018; 66:1290–7. - PMC - PubMed
    1. van Duin D, Lok JJ, Earley M, et al. ; Antibacterial Resistance Leadership Group Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163–71. - PMC - PubMed
    1. Shields RK, Nguyen MH, Chen L, et al. .. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017; 61:e00883–17. - PMC - PubMed
    1. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. . Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 2018; 7:439–55. - PMC - PubMed
    1. Motsch J, Murta de Oliveira C, Stus V, et al. .. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 2019; 70: 1799–808. - PMC - PubMed

Publication types